Royal Bank of Canada
INMB icon

Royal Bank of Canada’s INmune Bio INMB Stock Holding History

Royal Bank of Canada’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Buy
4,279
+1,595
+59% +$2.21K ﹤0.01% 6833
2026
Q1 		$3K Buy
2,684
+1,301
+94% +$1.85K ﹤0.01% 6593
2025
Q4 		$2K Sell
1,383
-933
-40% -$1.67K ﹤0.01% 6904
2025
Q3 		$5K Sell
2,316
-46,466
-95% -$106K ﹤0.01% 6699
2025
Q2 		$113K Buy
48,782
+18,919
+63% +$139K ﹤0.01% 5549
2025
Q1 		$233K Buy
29,863
+9,236
+45% +$73.3K ﹤0.01% 4587
2024
Q4 		$96K Sell
20,627
-41,459
-67% -$216K ﹤0.01% 5360
2024
Q3 		$334K Sell
62,086
-515
-0.8% -$3.66K ﹤0.01% 4416
2024
Q2 		$552K Sell
62,601
-20,135
-24% -$198K ﹤0.01% 3937
2024
Q1 		$973K Buy
82,736
+24,945
+43% +$301K ﹤0.01% 3485
2023
Q4 		$651K Sell
57,791
-14,892
-20% -$125K ﹤0.01% 4035
2023
Q3 		$492K Buy
72,683
+2,375
+3% +$19.7K ﹤0.01% 4051
2023
Q2 		$639K Buy
70,308
+9,769
+16% +$78.5K ﹤0.01% 3752
2023
Q1 		$391K Hold
60,539
– – ﹤0.01% 4073
2022
Q4 		$384K Buy
60,539
+11
+0% +$78 ﹤0.01% 4348
2022
Q3 		$375K Buy
60,528
+1,661
+3% +$14.6K ﹤0.01% 4261
2022
Q2 		$520K Buy
58,867
+7,261
+14% +$54K ﹤0.01% 4064
2022
Q1 		$434K Buy
51,606
+7,575
+17% +$68K ﹤0.01% 4382
2021
Q4 		$449K Sell
44,031
-82,380
-65% -$1.22M ﹤0.01% 4569
2021
Q3 		$2.46M Buy
126,411
+59,953
+90% +$1.16M ﹤0.01% 2903
2021
Q2 		$1.17M Buy
66,458
+910
+1% +$12.3K ﹤0.01% 3516
2021
Q1 		$779K Buy
65,548
+8,550
+15% +$154K ﹤0.01% 3809
2020
Q4 		$981K Buy
56,998
+56,894
+54,706% +$536K ﹤0.01% 3502
2020
Q3 		$1K Buy
104
+3
+3% +$31 ﹤0.01% 6438
2020
Q2 		$1K Buy
101
+11
+12% +$55 ﹤0.01% 6435
2020
Q1 		$0 Buy
+90
New +$406 ﹤0.01% 6831
2019
Q4 		– Sell
-30
Closed – – 6949
2019
Q3 		$0 Buy
+30
New +$222 ﹤0.01% 6890

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada's INMB Position: Q2 2026 in Review

Royal Bank of Canada increased its INmune Bio (INMB) stake by 59% in Q2 2026, buying an estimated $2.21K and bringing the position to 4,279 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6833.

Royal Bank of Canada first reported a position in INMB in Q3 2019 and has held it in 27 quarters since. The position peaked at $2.46M in Q3 2021. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Royal Bank of Canada held 4,279 shares of INmune Bio worth $7K as of Q2 2026.
  • Royal Bank of Canada bought 1,595 INmune Bio shares in Q2 2026, an estimated $2.21K.
  • INmune Bio made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6833 holding.
  • Royal Bank of Canada first reported a position in INmune Bio in Q3 2019 and has held it in 27 quarters since.
  • Royal Bank of Canada's INmune Bio position peaked at $2.46M in Q3 2021.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.